Together at the pulse
of neurology

ResearchSpectrumSolutions

Neuro Company

With a focus on the patient, EUROIMMUN develops and produces state-of-the-art test systems as one of the word’s leading manufacturers of medical laboratory diagnostics to aid in the diagnosis of diseases, as well as innovative automation and software solutions for effective and reliable processing and evaluation of such tests.

EUROIMMUN has its finger on the pulse of neurology through active basic research, a comprehensive and unique range of tests for the detection of neurobiomarkers, which is constantly being expanded on the basis of this research, and a service portfolio characterised by complete solutions for every laboratory.

Brochure » Video »

Discover our contribution to research

Patient-oriented fundamental research is a priority of EUROIMMUN. Our “Institute for Experimental Immunology” maintains collaborations with universities, clinics and renowned research facilities worldwide in order to study new antigens and develop innovative methods. This provides the foundation for the development of new test systems.

Patient storys - Anti-NMDAR encephalitis


A spectrum of neural autoantigens, newly identified by histo-immunoprecipitation, mass spectrometry and recombinant cell-based indirect immunofluorescence

A new method for the identification of new target antigens in neurological autoimmune diseases:

Scharf M, et al. A spectrum of neural autoantigens, newly identified by histo-immunoprecipitation, mass spectrometry and recombinant cell-based indirect immunofluorescence. Frontiers Immunol 9:1447 (2018).

Read more»
Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia

Discovery of septin-3 as an autoantibody target in patients with paraneoplastic cerebellar syndromes:

Miske R, et al. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia. J Neuroinflammation 20(1):88 (2023).

Read more»
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau

Guidelines for the preanalytical handling of CSF samples in order to reduce variability in measurement results:

Hansson O, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement 17(9):1575-1582 (2021).

Read more»

List of references

Important research contributions of EUROIMMUN in scientific articles of the last 5 years:

  1. Daguano Gastaldi V, et al. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immun 108:135-147 (2023).
  2. Discovery of Septin-3 as an autoantibody target in patients with paraneoplastic cerebellar syndromes:
    Miske R, et al. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia. J Neuroinflammation 20(1):88 (2023).
  3. Vilaseca A, et al. The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia. J Neurol 270(9):4533-4537 (2023).

  1. Álvarez I, et al. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol 28(4):1142-1152 (2021)
  2. Cirkel A, et al. Paraneoplastic encephalomyeloradiculitis with multiple autoantibodies against ITPR-1, GFAP and MOG: case report and literature review. Neurol Res Pract 3(1):48 (2021)
  3. International guidelines for the preanalytical handling of CSF samples in order to reduce variability in measurement results:
    Hansson O, et al. The Alzheimer’s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement 17(9):1575-1582 (2021)
  4. Identification of AP3B2 as an autoantigen in patients with ataxia:
    Honorat JA, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology 93(10):e954-e963 (2019)
  5. Evidence forthe association between autoantibodies against RGS8 and paraneoplastic cerebellar syndrome with lymphoma:
    Miske R, et al. Autoantibodies against the Purkinje cell protein RGS8 in paraneopastic cerebellar syndrome. Neurol Neuroimmunol Neuroinflamm 8(3):e987 (2021)
  6. Schanda K, et al. Differential binding of autoantibodies to MOG isoforms in inflammatory demyelinating diseases. Neurol Neuroimmunol Neuroinflamm 8(5):e1027 (2021)

  1. Bartels F, et al. Neuronal autoantibodies assiciated with cognitive impairment in melanoma patients. Ann Oncol 30(5):823-829 (2019).
  2. De Schaepdryver M, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol 6(10):1971-1979 (2019).
  3. Janelidze S, et al. Towards a unified protocol for handling of CSF before beta-amyloid measurements. Alzheimers Res Ther 11(1):63 (2019).
  4. O’Connor K, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm 6(3):e552 (2019).
  5. Schumacher M, et al. Encephalopathy associated with neurochondrin autoantibodies. J Child Neurol 34(11):660-665 (2019).
  6. Confirmation of neurochondrin as an autoantigen in further cases of neurological autoimmunity:
    Shelly S, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm 6(6), pii: e612 (2019).
  7. Palmqvist S, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 11(12):e11170 (2019).

  1. Alfugham N, et al. ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association. Neurol Neuroimmunol Neuroinflamm 5(1):e418 (2017).
  2. Berzero G, et al. Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurol Neuroimmunol Neuroinflamm 4(2):e326 (2017).
  3. Identification of anti-flotillin 1/2 autoantibodies in multiple sclerosis:
    Hahn S, et al. Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. J Neuroinflammation 14(1):123 (2017).
  4. Honorat JA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4(5):e385 (2017).
  5. Lang B, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry 88(4):353-361 (2017).
  6. Popkirov S, et al. Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. Acta Neuropathol Commun 5(1):40 (2017).
  7. Rommel FR, et al. Chorea minor associated with anti-neurochondrin autoantibodies. Neuropediatrics 48(6):482-483 (2017).
  8. Wilemse E, et al. How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio. Alzheimers Dement. 13(8):885-892 (2017).

EUROIMMUN – The Neuro Company

From research to all-round solutions for laboratories: Take a look behind the scenes and get to know highly motivated EUROIMMUNERs and their valuable contribution to neurodiagnostics.

Responsive image

Discover our solutions for diagnostics

Benefit from complete solutions for your laboratory: We offer not only a wide spectrum of diagnostic assays, but also innovative automation systems to meet your needs. Less hands-on time, more capacity. And you can count on our extensive advice and continuous support.

EUROIMMUN - Neuro-Company